Aneurysms at the origin of the posterior communicating artery (PcommA) have been demonstrated to be effectively treated with the pipeline embolization device (PED). Much less is known about the efficacy of the PED for aneurysms associated with a fetal posterior cerebral artery (fPCA) variant. OBJECTIVE: To study PED treatment efficacy of PcommA aneurysms, including fPCA aneurysms. METHODS: A prospectively maintained university database of aneurysm patients treated with the PED was retrospectively reviewed. Demographics, treatment details, and imaging were reviewed for all PcommA and fPCA aneurysms. RESULTS: Out of a total of 285 patients treated with PED, 50 patients (mean age 57.5 ± 12.2 yr, 42 females) with unruptured PcommA (9 fPCA) aneurysms were identified. Mean followup duration was 14.0 ± 11.6 mo (48 patients). Roy-Raymond class I occlusion on follow-up magnetic resonance or catheter angiography (mean time 11.7 ± 6.8 mo) was achieved in 30 patients (62.5%), class II occlusion in 11 patients (22.9%) and class III occlusion in 7 patients (14.5%). The PcommA was occluded in 56% of patients without any clinical symptoms. No deaths or permanent neurological complications occurred. In fPCA aneurysms, class I occlusion was seen in 1 patient, class 2 occlusion in 2 patients, and class III occlusion in 6 patients. Multivariate analysis revealed an independent association between incomplete occlusion and fPCA configuration (OR 73.65; 95% CI: 5.84-929.13; P = .001).
aneurysms of the proximal internal carotid artery (ICA). 1 Additionally, the PED has been increasingly used for off-label treatment of both smaller anterior and posterior circulation aneurysms. [1] [2] [3] [4] Several recent reports have demonstrated that aneurysms of the ICA at the origin of the posterior communicating artery (PcommA) can be effectively treated with the PED (Medtronic) with acceptable rates of occlusion but varying degrees of PcommA patency. 5, 6 Fetal origin of the posterior cerebral artery (fPCA) is a common anatomic variant whereby there is agenesis of the P1 segment and the PCA is a continuation of the PcommA. The prevalence of fPCA is estimated to range between 4% and 29%. 7 Scarce data NEUROSURGERY VOLUME 82 | NUMBER 5 | MAY 2018 | 695 are available regarding the efficacy of treating aneurysms that arise from the ICA at the origin of an fPCA using the PED. Such aneurysms are challenging to treat with traditional coiling or balloon-assisted coil embolization, and complete occlusion is difficult to achieve without risking partial or complete obstruction of the fPCA. Consequently, treatment of fPCA aneurysms by flow diversion is conceptually appealing but unproven in terms of efficacy and safety. Here, we present the largest series of patients with ICA aneurysms at the origin of the PcommA or fPCA treated with the PED. Additionally, the existing literature on treatment of fPCA aneurysms using the PED is reviewed.
METHODS
The local Institutional Review Board approved this study with a waiver of informed consent. A prospectively maintained database of consecutive patients whose aneurysms were treated with the PED (Medtronic) was retrospectively reviewed. All patients treated for unruptured PcommA aneurysms were identified. We defined the fPCA subgroup by the absence of a P1 segment on pretreatment digital subtraction angiography (DSA). Demographic information, aneurysm characteristics, treatment details including antiplatelet regimen, and follow-up data were extracted from the medical record. Aneurysm occlusion was graded on the Roy-Raymond scale. 8, 9 All peri-and postprocedural complications were recorded.
All patients were premedicated with dual antiplatelet therapy. Platelet function tests were performed per center protocol. All patients demonstrated optimal platelet activity suppression prior to placement of a PED. Fellowship-trained neuroendovascular surgeons performed all procedures. Intravenous heparin was administered intraprocedurally to achieve an activated clotting time greater than 250 s. Heparin was discontinued upon conclusion of the procedure. Dual antiplatelet therapy was continued for 6 mo after the PED placement.
Continuous 
RESULTS

Patient Data
Out of a total of 285 aneurysm patients treated with PED (Medtronic), 50 patients with 50 PcommA aneurysms treated using at least 1 PED were identified. Some patients harbored tandem, ipsilateral, ICA aneurysms also treated by the PED construct for a total of 73 treated aneurysms. The mean age of the group was 57.5 ± 12.2 yr. There were 8 (16%) males and 42 (84%) females in the group. The median maximal diameter of PcommA aneurysms was 6.4 (4-11.1) mm and the median neck size was 4.0 (2.8-4.8) mm. Two PEDs were used in 4 patients and 3 PEDs in 2 patients. All other patients underwent treatment with a single PED. Flow diversion was indicated after recurrence following prior coiling in 19 (38%) patients. Adjunctive coiling was performed in 10 (20%) pipeline embolization procedures.
Radiographic Outcomes
Postprocedural follow-up imaging-either time-of-flight, time-resolved Magnetic Resonance Angiography (MRA) or digital DSA-was available for 48 (96%) patients. Mean radiographic follow-up duration was 14.0 ± 11.6 mo. PcommA patency was evaluated in 25 patients who underwent follow-up DSA, and 11 vessels remained open (44%). We only relied on the DSA for PcommA patency given the lack of validated, reliable technique for assessing patency on MRA. PcommA occlusion was clinically silent in the remaining patients. RoyRaymond class I aneurysm occlusion ( Figure 1 ) was achieved in 30 (62.5%) patients, while class II occlusion was seen in 11 (22.9%) patients and class III occlusion was seen in 7 (14.5%) patients. Within the cohort, 9 patients (mean age 58.8 ± 13.2 yr, 6 females) were treated for fPCA aneurysms, 4 of whom had at least 1 tandem ICA aneurysm within the confines of the PED for a total of 14 treated aneurysms (Table 1 ). All the fPCA aneurysms had necks that incorporated the origin of the fPCA. The median, maximal diameter of treated fPCA aneurysms was 7.6 [4.8-11.5] mm and the median neck size was 4.6 [3.2-5.9] mm. All aneurysms were treated with a single PED. There were 2 patients who underwent retreatment after prior coiling and 1 patient who underwent adjunctive coiling. Mean follow-up duration was 11.7 ± 6.8 mo based on the most recent postprocedural imaging (timeof-flight, time-resolved MRA or DSA). Follow-up radiographic data was available for all patients in the fPCA subgroup. The fPCA was occluded in a single patient ( Figure 2 ) and patent in all other patients. No patients had any symptoms from the occlusion or covering of the fPCA. Complete occlusion was achieved for 1 aneurysm (Roy-Raymond class I), while minimal filling of the neck was present in 2 aneurysms (Roy-Raymond class II) and incomplete occlusion (Figure 3 ) was seen in 6 aneurysms (RoyRaymond class III).
We separately analyzed patients with a dominant PcommA, which was defined as a vessel larger than the P1 when the P1 was present. There were 9 such patients in the non-fPCA group. Follow-up data was available for 8 of these aneurysms. Roy- Raymond class I aneurysm occlusion was achieved in 3 patients, while class II occlusion was seen in 4 patients and class III occlusion was seen in 1 patient. Table 2 details the differences between the Roy-Raymond class I/II and Roy-Raymond class III groups. The probability of an incomplete occlusion was significantly higher in the fPCA subgroup of patients (86% vs 7%, P < .001). The multivariate model indicated an independent association between the dependent variable of incomplete aneurysm occlusion and the independent variables of fPCA-related aneurysm (OR 73.65; 95% CI: 5.84-929.13; P = .001).
Patient Outcomes
Forty-nine patients (98%) were seen in follow-up, and all patients were at their baseline or better by the modified Rankin scale. The only periprocedural neurological complication for the entire group was a postprocedural generalized tonic-clonic seizure in a patient who was discharged at neurological baseline on postprocedure day 3. Other complications included 3 instances of gastrointestinal bleeding, 2 retroperitoneal hematomas after follow-up DSA, 1 episode of epistaxis, and 1 patient with a superficial skin abscess at the femoral puncture site. Two of the patients with gastrointestinal bleeding required a transfusion, and one of them was found to have a stomach ulcer, at which point that patient was placed on clopidogrel monotherapy. One patient had a transient ischemic attack 2 mo after PED placement and was later found to have a small, ipsilateral, corona radiata infarct. At the time, the patient was already compliant on aspirin and prasugrel, and this was continued after additional platelet function testing. DSA revealed that her PcommA continued to fill. The patient has remained asymptomatic as of a 3-yr postprocedural follow-up.
DISCUSSION
This report details a single university experience wherein the PED (Medtronic) was used to treat PcommA aneurysms. To the best of our knowledge, this is the largest reported series on PED treatment of PcommA aneurysms. Overall, complete or near complete occlusion (Roy-Raymond class 1 or 2) was achieved in 85.4% of patients in this series with no major neurological complications. Daou et al 5 recently published results for PED treatment of PcommA aneurysms with a 6-mo follow-up and reported complete or near complete obliteration in 26 of 30 aneurysms (86.7%), which is comparable to our series. These data are comparable to larger, previously published reports, such as the seminal Pipeline for uncoilable or failed aneurysms (PUFS) trial, 10 which included ICA aneurysms from the petrous to the superior hypophyseal segment and reported complete occlusion in 86.8% of all aneurysms at 1 yr.
Although aneurysm occlusion rates are similar across studies, significant variability has been reported for patency of ICA branch vessels covered by the PED. Brinjikji et al 11 analyzed 13 aneurysms in which the PcommA ostium was covered by a PED and reported 3 PcommA occlusions and 2 with diminished flow after mean follow-up of 12.6 mo. Daou et al 5 reported occlusion of the PcommA in 53.3% of patients and diminished flow in 23.3% of patients in similar cases. Vedantam et al 12 recently published branch occlusion in 7.1% of PcommA overlaid in the treatment of ICA aneurysms generally. Occlusion of the PcommA was clinically silent in all cases in these cohorts. Whether the PcommA functions as a collateral or as an end vessel, such as in the fPCA variant, is likely a key determinant for subsequent occlusion when the ostium is covered by PED, as increased flow demand is likely a contributing factor to vessel patency.
The rate of fPCA aneurysm occlusion or near-occlusion was low in our series (33% Roy-Raymond class I or II), which is similar to previous reports. Chen et al 13 published a series of 9 patients, treated endovascularly, for aneurysms of the ICA at the origin of an fPCA. While 7 of 9 aneurysms were embolized using adjunctive methods, such as balloon-or stent-assisted coiling, complete aneurysm occlusion was achieved in 8 patients. Yao et al 14 compared small PcommA aneurysms treated by coiling with or without stenting. A total of 114 PcommA aneurysms were included, of which 55 were at the origin of an fPCA. At median follow-up of slightly greater than 1 yr, aneurysm recurrence rates were 4.4% and 30.2% in stent-assisted and coiling only groups, respectively. The study did not, however, separately report the occlusion rate of the fPCA aneurysms.
fPCA Literature Review
Review of the literature revealed 3 studies in which patients were treated with the PED specifically for fPCA aneurysms for a total of 14 cases. 5, 15, 16 In a series of 29 aneurysms treated with the PED, Tsang et al 15 reported 4 fPCA aneurysms, all of which continued to opacify on the 18-mo follow-up imaging. Daou et al 5 studied the patency of the PcommA following PED placement in 30 patients with PcommA aneurysms treated by PED, 6 of whom had the fPCA variant. Aneurysm occlusion in the fPCA aneurysm group was 66.7% compared to 87.5% in those with an aneurysm at the origin of a typical PcommA. Furthermore, none of the fPCAs were completely occluded (3 were patent; 3 had diminished flow with no clinical sequelae). Both univariate and multivariate analysis revealed that the presence of an fPCA variant was associated with branch vessel patency after PED placement. The number of PEDs used was not associated with PcommA or fPCA patency. Kan et al 16 investigated treatment efficacy of the PED in a case series that included 4 patients who harbored fPCA aneurysms. None of the aneurysms were successfully obliterated on an 18-mo follow-up angiogram despite 3 of 4 having been treated with adjunctive coiling. In sum, the available data added to the current series indicate that flow diversion for the treatment of fPCA aneurysms is associated with a low rate of aneurysm occlusion (5/23 or 22%; Table 3 ).
The putative mechanism for treatment failure of fPCA aneurysms using the PED is that high flow demand maintains fPCA patency and serves as an in-flow jet sufficient to prevent thrombosis of the aneurysm. Although the only complete fPCA aneurysm occlusion in our series underwent prior coiling, Open surgical series have also demonstrated excellent results with clipping. 17, 18 From a surgical standpoint, PcommA aneurysms have traditionally been very favorable for clipping. They do not require extensive microsurgical dissection and can be approached via a standard pterional craniotomy. Sanai et al 18 reviewed the surgical treatment of PcommA aneurysms during an 11-yr period and found a total of 218 PcommA aneurysms. Complete occlusion was reported in 94.8% of patients with minimal residual aneurysm seen in 5.2% of cases. There were no incomplete occlusions. Although excellent angiographic results were seen, the authors report that neurological outcomes were less favorable because one-fourth of the patients had a poor grade (Hunt-Hess IV and V). In the Sanai et al 18 study, 23 fetal PcommA aneurysms were surgically treated within the total group of 218 PcommA aneurysms. The presence of a fetal PcommA was not associated with a difference in neurological outcome after clipping. Zada et al 17 reviewed the treatment of 30 fetal PcommA aneurysms from an overall pool of 273 PcommA aneurysms at a high-volume center over a 15-yr period. Within the group of fetal PcommA aneurysms, 24 underwent surgical clipping and 6 underwent endovascular coiling. The overall patency of the fPCA was 96% in the surgical group and 100% in the coiling group after treatment. There were no procedural complications seen in the coiling group, which could be attributed to careful preoperative evaluation for effective coiling. One patient in the coiling group required retreatment with coiling 3 mo after the initial treatment.
Limitations
We believe fPCA aneurysms should strongly be considered for traditional endovascular management including intrasaccular approaches or surgical clipping. However, it should be noted that the mean follow-up in the current series was approximately 1 yr. Continued longitudinal analysis will reveal if occlusion rates for fPCA aneurysms treated with PED improve over a protracted period.
Additional unanswered questions remain regarding treatment efficacy for PcommA aneurysms treated with the PED. The longterm rupture rate for persistent Roy-Raymond class II and III occlusions with the PED is undefined. Persistent surveillance is crucial in our understanding of this technology.
CONCLUSION
PEDs (Medtronic) are a safe and effective choice in the treatment of PcommA aneurysms. The presence of fetal anatomy, however, should increase consideration of traditional intrasaccular endovascular techniques or surgical clipping. Longer follow-up is needed to determine the ultimate efficacy of PED treatment for these aneurysms.
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